Fixed dose combination formulations for treating pain
Fixed-dose combination drugs comprising an NSAID as a first drug component and a GABA-type calcium channel blocker as a second drug component are contemplated. Further contemplated aspects also include methods of administration of combination drugs and drugs contained herein.
1. A fixed-dose combination drug, comprising:
an NSAID (non-steroidal anti-inflammatory drug) as a first drug component in a first layer, and a GABA (gamma- aminobutyric acid)-type calcium channel blocker as a second drug component in a second layer;
wherein the NSAID is acetaminophen and wherein the GABA (gamma-aminobutyric acid)-type calcium channel blocker is pregabalin;
wherein the fixed-dose combination drug is formulated for oral administration such that a single oral dosage unit contains the first layer coupled and adjacent to the second layer, and wherein the fixed-dose combination drug provides upon oral administration in the single dosage unit to an individual in need thereof the NSAID in a sustained release in which cumulatively between 40-80% of the NSAID are released over a period of six to eight hours, and the GABA-type calcium channel blocker in a sustained release in which cumulatively between 40-80% of the GABA-type calcium channel blocker are released over a period of two hours.
2. The fixed-dose combination drug of claim 1 , containing the NSAID in an amount of between 250 mg and 1500 mg.
3. The fixed-dose combination drug of claim 1 , containing the NSAID in an amount of between 500 mg and 1300 mg.
4. The fixed-dose combination drug of claim 2 , containing the GABA-type calcium channel blocker in an amount of between 5 mg and 600 mg.
5. The fixed-dose combination drug of claim 3 , containing the GABA-type calcium channel blocker in an amount of between 10 mg and 600 mg.
6. The fixed-dose combination drug of claim 1 , containing the GABA-type calcium channel blocker in an amount of between 5 mg and 100 mg.
7. The fixed-dose combination drug of claim 1 , containing the GABA-type calcium channel blocker in an amount of between 10 mg and 50 mg.
8. The fixed-dose combination drug of claim 1 , wherein cumulatively between 60-80% of the NSAID in the sustained release is released over a period of two hours.
9. The fixed-dose combination drug of claim 1 , wherein cumulatively between 60-80% of the GABA-type calcium channel blocker in the sustained release is released over a period of six to eight hours.